TenX BioPharma - Monoclonal Antibody Cancer Therapy - Ownership and Business Overview

Life ScienceCompany

TenX BioPharma - Monoclonal Antibody Cancer Therapy Ownership

Who owns TenX BioPharma - Monoclonal Antibody Cancer Therapy?

TenX BioPharma - Monoclonal Antibody Cancer Therapy is owned by Emergent BioSolutions. It was acquired on June 6, 2011.

TenX BioPharma - Monoclonal Antibody Cancer Therapy Business Overview

Where is TenX BioPharma - Monoclonal Antibody Cancer Therapy headquartered?

TenX BioPharma - Monoclonal Antibody Cancer Therapy is headquartered in United States.

What sector is TenX BioPharma - Monoclonal Antibody Cancer Therapy in?

TenX BioPharma - Monoclonal Antibody Cancer Therapy is a life science company.

Life Science M&A Summary in 2011

Out of 60 sectors in the Mergr database, life science ranked 11 in number of deals in 2011. The largest life science acquisition in 2011 was Genzyme - which was acquired by Sanofi SA for $20.1B.

Join Mergr to view all 171 acquisitions of life science companies in 2011, including 23 acquisitions by private equity firms, and 148 by strategics.

TenX BioPharma - Monoclonal Antibody Cancer Therapy


United States,

TenX BioPharma - Monoclonal Antibody Cancer Therapy includes rights to zanolimumab, an investigational, late-stage monoclonal antibody cancer therapy targeting T-cell lymphomas. Zanolimumab has been evaluated in 130 T-cell lymphoma patients to date. Zanolimumab has received fast track and orphan drug status from the U.S. Food and Drug Administration, and orphan drug status from the European Medicines Agency.


 Subscribe to unlock this and 206,305
investor and company profiles

Sign-up today to get full access

  • check  Unlimited Searches
  • check  Unlimited Profile Views
  • check  Build and Export Lists of
    • PE Backed Companies
    • Direct Investors & Acquirers
    • Advisors
    • Deals
    • & More

What's Mergr?

We built Mergr to save people the arduous and time-consuming process of tracking when companies are bought, sold, and who currently owns them.

Every day, new opportunities emerge around M&A and we help professionals of all types comb through transactions, investors, and corporate acquirers via an easy-to-use web database that is accessible to anyone.

Try us for 1 week free today!

Mergr, the Easiest-to-Use PE and M&A DB


Key Benefits

  • Stay informed on events in your industry
  • M&A research that takes seconds (not all afternoon)
  • Better understand your customers and prospects
  • Discover active buyers (or sellers)
Search
  • 4.6K Private Equity Firms
  • 198K M&A Transactions
  • 202K Companies Involved in M&A
    (Buyer, Seller, or Target)
  • 3.6K M&A Advisors
    (Investment Banks and Law Firms)
  • 80K M&A Contacts
    (PE and M&A Advisors)

Ready to try?

Join FREE for 1 Week

No obligation. Cancel anytime.

Related Lists for TenX BioPharma - Monoclonal Antibody Cancer Therapy

Life Science Companies , United States Companies